Patents by Inventor John David Trzupek

John David Trzupek has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Bicyclic-Fused Heteroaryl or Aryl Compounds
    Publication number: 20230339960
    Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. In an embodiment, a pharmaceutical composition can be in a liquid dosage form and can comprise a therapeutically effective amount of the compound or a pharmaceutically acceptable salt thereof as an adjuvant and a therapeutic agent. In another embodiment, a method of adjuvant treating a disorder or condition can comprising administering the pharmaceutical composition to a patient.
    Type: Application
    Filed: June 28, 2023
    Publication date: October 26, 2023
    Inventors: JOHN DAVID TRZUPEK, KATHERINE LIN LEE, MARK EDWARD BUNNAGE, SEUNGIL HAN, DAVID HEPWORTH, FRANK ELDRIDGE LOVERING, JOHN PAUL MATHIAS, NIKOLAOS PAPAIOANNOU, BETSY SUSAN PIERCE, JOSEPH WALTER STROHBACH, STEPHEN WAYNE WRIGHT, CHRISTOPH WOLFGANG ZAPF, LORI KRIM GAVRIN, ARTHUR LEE, DAVID RANDOLPH ANDERSON, KEVIN JOSEPH CURRAN, CHRISTOPH MARTIN DEHNHARDT, EDDINE SAIAH, JOEL ADAM GOLDBERG, XIAOLUN WANG, HORNG-CHIH HUANG, RICHARD VARGAS, MICHAEL DENNIS LOWE, AKSHAY PATNY
  • Bicyclic-fused heteroaryl or aryl compounds
    Patent number: 11702424
    Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
    Type: Grant
    Filed: August 18, 2020
    Date of Patent: July 18, 2023
    Assignee: Pfizer Inc.
    Inventors: John David Trzupek, Katherine Lin Lee, Mark Edward Bunnage, Seungil Han, David Hepworth, Frank Eldridge Lovering, John Paul Mathias, Nikolaos Papaioannou, Betsy Susan Pierce, Joseph Walter Strohbach, Stephen Wayne Wright, Christoph Wolfgang Zapf, Lori Krim Gavrin, Arthur Lee, David Randolph Anderson, Kevin Joseph Curran, Christoph Martin Dehnhardt, Eddine Saiah, Joel Adam Goldberg, Xiaolun Wang, Horng-Chih Huang, Richard Vargas, Michael Dennis Lowe, Akshay Patny
  • Bicyclic-Fused Heteroaryl or Aryl Compounds
    Publication number: 20200377511
    Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
    Type: Application
    Filed: August 18, 2020
    Publication date: December 3, 2020
    Applicant: Pfizer Inc.
    Inventors: John David Trzupek, Katherine Lin Lee, Mark Edward Bunnage, Seungil Han, David Hepworth, Frank Eldridge Lovering, John Paul Mathias, Nikolaos Papaioannou, Betsy Susan Pierce, Joseph Walter Strohbach, Stephen Wayne Wright, Christoph Wolfgang Zapf, Lori Krim Gavrin, Arthur Lee, David Randolph Anderson, Kevin Joseph Curran, Christoph Martin Dehnhardt, Eddine Saiah, Joel Adam Goldberg, Xiaolun Wang, Horng-Chih Huang, Richard Vargas, Michael Dennis Lowe, Akshay Patny
  • Bicyclic-fused heteroaryl or aryl compounds
    Patent number: 10793579
    Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
    Type: Grant
    Filed: May 14, 2019
    Date of Patent: October 6, 2020
    Assignee: Pfizer Inc.
    Inventors: John David Trzupek, Katherine Lin Lee, Mark Edward Bunnage, Seungil Han, David Hepworth, Frank Eldridge Lovering, John Paul Mathias, Nikolaos Papaioannou, Betsy Susan Pierce, Joseph Walter Strohbach, Stephen Wayne Wright, Christoph Wolfgang Zapf, Lori Krim Gavrin, Arthur Lee, David Randolph Anderson, Kevin Joseph Curran, Christoph Martin Dehnhardt, Eddine Saiah, Joel Adam Goldberg, Xiaolun Wang, Horng-Chih Huang, Richard Vargas, Michael Dennis Lowe, Akshay Patny
  • Methyl- and Trifluromethyl-Substituted Pyrrolopyridine Modulators of RORC2 and Methods of Use Thereof
    Publication number: 20190387710
    Abstract: The present invention provides methyl- and trifluoromethyl-substituted pyrrolopyridines, pharmaceutical compositions thereof, methods of modulating ROR? activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such pyrrolopyridines and pharmaceutical compositions thereof.
    Type: Application
    Filed: September 6, 2019
    Publication date: December 26, 2019
    Applicant: Pfizer Inc.
    Inventors: Mark Edward Schnute, Andrew Christopher Flick, Peter Jones, Neelu Kaila, Scot Richard Mente, John David Trzupek, Michael L. Vazquez, Goran Mattias Wennerstal, Li Xing, Edouard Zamaratski, Liying Zhang, Rayomand Jal Unwalla
  • Methyl- and trifluromethyl-substituted pyrrolopyridine modulators of RORC2 and methods of use thereof
    Patent number: 10426135
    Abstract: The present invention provides methyl- and trifluoromethyl-substituted pyrrolopyridines, pharmaceutical compositions thereof, methods of modulating ROR? activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such pyrrolopyridines and pharmaceutical compositions thereof.
    Type: Grant
    Filed: February 6, 2019
    Date of Patent: October 1, 2019
    Assignee: Pfizer Inc.
    Inventors: Mark Edward Schnute, Andrew Christopher Flick, Peter Jones, Neelu Kaila, Scot Richard Mente, John David Trzupek, Michael L. Vazquez, Goran Mattias Wennerstal, Li Xing, Edouard Zamaratski, Liying Zhang, Rayomand Jal Unwalla
  • Bicyclic-Fused Heteroaryl or Aryl Compounds
    Publication number: 20190270751
    Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
    Type: Application
    Filed: May 14, 2019
    Publication date: September 5, 2019
    Applicant: Pfizer Inc.
    Inventors: John David Trzupek, Katherine Lin Lee, Mark Edward Bunnage, Seungil Han, David Hepworth, Frank Eldridge Lovering, John Paul Mathias, Nikolaos Papaioannou, Betsy Susan Pierce, Joseph Walter Strohbach, Stephen Wayne Wright, Christoph Wolfgang Zapf, Lori Krim Gavrin, Arthur Lee, David Randolph Anderson, Kevin Joseph Curran, Christoph Martin Dehnhardt, Eddine Saiah, Joel Adam Goldberg, Xiaolun Wang, Horng-Chih Huang, Richard Vargas, Michael Dennis Lowe, Akshay Patny
  • Sulfonamide-substituted indole modulators of RORC2 and methods of use thereof
    Patent number: 10385036
    Abstract: The present invention provides sulfonamide-substituted indoles and Methods of Use Thereof-substituted pyrrolopyridines, pharmaceutical compositions thereof methods of modulating RORy activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such indoles and pharmaceutical compositions thereof.
    Type: Grant
    Filed: January 29, 2016
    Date of Patent: August 20, 2019
    Assignee: Pfizer Inc.
    Inventors: Mark Edward Schnute, Andrew Christopher Flick, Peter Jones, Neelu Kaila, Scot Richard Mente, John David Trzupek, Michael L. Vazquez, Goran Mattias Wennerstal, Li Xing, Edouard Zamaratski, Liying Zhang, Rayomand J. Unwalla
  • Methyoxy-substituted pyrrolopyridine modulators of RORC2 and methods of use thereof
    Patent number: 10336748
    Abstract: The present invention provides methoxy-substituted pyrrolopyridines, pharmaceutical compositions thereof, methods of modulating ROR? activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such pyrrolopyridines and pharmaceutical compositions thereof.
    Type: Grant
    Filed: January 29, 2016
    Date of Patent: July 2, 2019
    Assignee: Pfizer Inc.
    Inventors: Mark Edward Schnute, Andrew Christopher Flick, Peter Jones, Neelu Kaila, Scot Richard Mente, John David Trzupek, Michael L. Vazquez, Goran Mattias Wennerstal, Li Xing, Edouard Zamaratski, Liying Zhang, Rayomand J. Unwalla
  • Bicyclic-fused heteroaryl or aryl compounds
    Patent number: 10329302
    Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
    Type: Grant
    Filed: January 5, 2018
    Date of Patent: June 25, 2019
    Assignee: Pfizer Inc.
    Inventors: John David Trzupek, Katherine Lin Lee, Mark Edward Bunnage, Seungil Han, David Hepworth, Frank Eldridge Lovering, John Paul Mathias, Nikolaos Papaioannou, Betsy Susan Pierce, Joseph Walter Strohbach, Stephen Wayne Wright, Christoph Wolfgang Zapf, Lori Krim Gavrin, Arthur Lee, David Randolph Anderson, Kevin Joseph Curran, Christoph Martin Dehnhardt, Eddine Saiah, Joel Adam Goldberg, Xiaolun Wang, Horng-Chih Huang, Richard Vargas, Michael Dennis Lowe, Akshay Patny
  • Bicyclic-fused heteroaryl or aryl compounds as IRAK4 modulators
    Patent number: 10316018
    Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
    Type: Grant
    Filed: November 30, 2018
    Date of Patent: June 11, 2019
    Assignee: Pfizer Inc.
    Inventors: Katherine Lin Lee, Christophe Philippe Allais, Christoph Martin Dehnhardt, Lori Krim Gavrin, Seungil Han, David Hepworth, Arthur Lee, Frank Eldridge Lovering, John Paul Mathias, Dafydd Rhys Owen, Nikolaos Papaioannou, Eddine Saiah, Joseph Walter Strohbach, John David Trzupek, Stephen Wayne Wright, Christoph Wolfgang Zapf
  • Methyl- and Trifluromethyl-Substituted Pyrrolopyridine Modulators of RORC2 and Methods of Use Thereof
    Publication number: 20190150401
    Abstract: The present invention provides methyl- and trifluoromethyl-substituted pyrrolopyridines, pharmaceutical compositions thereof, methods of modulating ROR? activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such pyrrolopyridines and pharmaceutical compositions thereof.
    Type: Application
    Filed: February 6, 2019
    Publication date: May 23, 2019
    Applicant: Pfizer Inc.
    Inventors: Mark Edward Schnute, Andrew Christopher Flick, Peter Jones, Neelu Kaila, Scot Richard Mente, John David Trzupek, Michael L. Vazquez, Goran Mattias Wennerstal, Li Xing, Edouard Zamaratski, Liying Zhang, Rayomand Jal Unwalla
  • BICYCLIC-FUSED HETEROARYL OR ARYL COMPOUNDS AS IRAK4 MODULATORS
    Publication number: 20190092750
    Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula 1a, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
    Type: Application
    Filed: November 30, 2018
    Publication date: March 28, 2019
    Applicant: PFIZER INC.
    Inventors: KATHERINE LIN LEE, CHRISTOPHE PHILIPPE ALLAIS, CHRISTOPH MARTIN DEHNHARDT, LORI KRIM GAVRIN, SEUNGIL HAN, DAVID HEPWORTH, ARTHUR LEE, FRANK ELDRIDGE LOVERING, JOHN PAUL MATHIAS, DAFYDD RHYS OWEN, NIKOLAOS PAPAIOANNOU, EDDINE SAIAH, JOSEPH WALTER STROHBACH, JOHN DAVID TRZUPEK, STEPHEN WAYNE WRIGHT, CHRISTOPH WOLFGANG ZAPF
  • Methyl- and trifluoromethyl-substituted pyrrolopyridine modulators of RORC2 and methods of use therof
    Patent number: 10227346
    Abstract: The present invention provides methyl- and trifluoromethyl-substituted pyrrolopyridines, pharmaceutical compositions thereof, methods of modulating ROR? activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such pyrrolopyridines and pharmaceutical compositions thereof.
    Type: Grant
    Filed: February 6, 2018
    Date of Patent: March 12, 2019
    Assignee: Pfizer Inc.
    Inventors: Mark Edward Schnute, Andrew Christopher Flick, Peter Jones, Neelu Kaila, Scot Richard Mente, John David Trzupek, Michael L. Vazquez, Goran Mattias Wennerstal, Li Xing, Edouard Zamaratski, Liying Zhang, Rayomand Jal Unwalla
  • Bicyclic-fused heteroaryl or aryl compounds as IRAK4 modulators
    Patent number: 10174000
    Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
    Type: Grant
    Filed: August 16, 2016
    Date of Patent: January 8, 2019
    Assignee: Pfizer Inc.
    Inventors: Katherine Lin Lee, Christophe Philippe Allais, Christoph Martin Dehnhardt, Lori Krim Gavrin, Seungil Han, David Hepworth, Arthur Lee, Frank Eldridge Lovering, John Paul Mathias, Dafydd Rhys Owen, Nikolaos Papaioannou, Eddine Saiah, Joseph Walter Strohbach, John David Trzupek, Stephen Wayne Wright, Christoph Wolfgang Zapf
  • Sulfonamide-Substituted Indole Modulators of RORC2 and Methods of Use Thereof
    Publication number: 20180273504
    Abstract: The present invention provides sulfonamide-substituted indoles and Methods of Use Thereof-substituted pyrro-lopyridines, pharmaceutical compositions thereof methods of modulating RORy activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such indoles and pharmaceutical compositions thereof.
    Type: Application
    Filed: January 29, 2016
    Publication date: September 27, 2018
    Applicant: Pfizer Inc.
    Inventors: Mark Edward Schnute, Andrew Christopher Flick, Peter Jones, Neelu Kaila, Scot Richard Mente, John David Trzupek, Michael L. Vazquez, Goran Mattias Wennerstal, Li Xing, Edouard Zamaratski, Liying Zhang, Rayomand J. Unwalla
  • BICYCLIC-FUSED HETEROARYL OR ARYL COMPOUNDS AS IRAK4 MODULATORS
    Publication number: 20180244646
    Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
    Type: Application
    Filed: August 16, 2016
    Publication date: August 30, 2018
    Applicant: PFIZER INC.
    Inventors: KATHERINE LIN LEE, CHRISTOPHE PHILIPPE ALLAIS, CHRISTOPH MARTIN DEHNHARDT, LORI KRIM GAVRIN, SEUNGIL HAN, DAVID HEPWORTH, ARTHUR LEE, FRANK ELDRIDGE LOVERING, JOHN PAUL MATHIAS, DAFYDD RHYS OWEN, NIKOLAOS PAPAIOANNOU, EDDINE SAIAH, JOSEPH WALTER STROHBACH, JOHN DAVID TRZUPEK, STEPHEN WAYNE WRIGHT, CHRISTOPH WOLFGANG ZAPF
  • Bicyclic-Fused Heteroaryl Or Aryl Compounds
    Publication number: 20180230127
    Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds of Formula (Ia) are disclosed which are inhibitors of Interleukin-1 receptor associated kinase (IRAK4). Methods of treatment, methods of synthesis, and intermediates are also disclosed as defined in the specification.
    Type: Application
    Filed: July 29, 2016
    Publication date: August 16, 2018
    Applicant: PFIZER INC.
    Inventors: DAVID RANDOLPH ANDERSON, Kevin Joseph CURRAN, Lori Krim GAVRIN, Joel Adam GOLDBERG, Arthur LEE, Michael Dennis LOWE, Akshay Patny, Betsy Susan PIERCE, Eddine SAIAH, John David TRZUPEK
  • Methyl- and Trifluoromethyl-Substituted Pyrrolopyridine Modulators of RORC2 and Methods of Use Thereof
    Publication number: 20180170928
    Abstract: The present invention provides methyl- and trifluoromethyl-substituted pyrrolopyridines, pharmaceutical compositions thereof, methods of modulating ROR? activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such pyrrolopyridines and pharmaceutical compositions thereof.
    Type: Application
    Filed: February 6, 2018
    Publication date: June 21, 2018
    Applicant: Pfizer Inc.
    Inventors: MARK EDWARD SCHNUTE, ANDREW CHRISTOPHER FLICK, PETER JONES, NEELU KAILA, SCOT RICHARD MENTE, JOHN DAVID TRZUPEK, MICHAEL L. VAZQUEZ, GORAN MATTIAS WENNERSTAL, LI XING, EDOUARD ZAMARATSKI, LIYING ZHANG
  • Bicyclic-Fused Heteroaryl or Aryl Compounds
    Publication number: 20180127432
    Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
    Type: Application
    Filed: January 5, 2018
    Publication date: May 10, 2018
    Applicant: Pfizer Inc.
    Inventors: John David Trzupek, Katherine Lin Lee, Mark Edward Bunnage, Seungil Han, David Hepworth, Frank Eldridge Lovering, John Paul Mathias, Nikolaos Papaioannou, Betsy Susan Pierce, Joseph Walter Strohbach, Stephen Wayne Wright, Christoph Wolfgang Zapf, Lori Krim Gavrin, Arthur Lee, David Randolph Anderson, Kevin Joseph Curran, Christoph Martin Dehnhardt, Eddine Saiah, Joel Adam Goldberg, Xiaolun Wang, Horng-Chih Huang, Richard Vargas, Michael Dennis Lowe, Akshay Patny